EGFRvIII peptide PEPvIII |
| Catalog No.GC35967 |
EGFRvIII 펩타이드 PEPvIII는 다형성 교모세포종(GBM) 및 기타 신생물에서 널리 발현되는 종양 특이적 돌연변이이며 이의 발현은 종양형성을 향상시킨다. EGFRvIII 펩타이드는 항종양 면역요법을 위한 진정한 종양 특이적 표적을 나타냅니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129112-17-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy[1].
[1]. Schmittling RJ, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74-81.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *